A Director at CryoPort is Exercising Options

By Carrie Williams

Yesterday it was reported that a Director at CryoPort (CYRXResearch Report), Richard J. Berman, exercised options to sell 5,000 CYRX shares at $3.07 a share, for a total transaction value of $75.05K.

In addition to Richard J. Berman, one other CYRX executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on CryoPort’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $9.58 million and GAAP net loss of $12.47 million. In comparison, last year the company earned revenue of $5.29 million and had a GAAP net loss of $2.14 million. The company has a one-year high of $25.02 and a one-year low of $8.28. Currently, CryoPort has an average volume of 381.82K.

In the last 30 days, insiders have sold $241.9K worth of CYRX shares and purchased $46.98K worth of CYRX shares. The insider sentiment on CryoPort has been neutral according to 13 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.